Comparative Pharmacology
Head-to-head clinical analysis: FML versus INVELTYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML versus INVELTYS.
FML vs INVELTYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to inhibition of phospholipase A2 via annexin-1 induction, reducing prostaglandin and leukotriene synthesis; also suppresses cytokine production and inflammatory cell migration.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
Fluorometholone ophthalmic suspension 0.1%: Instill 1 drop into conjunctival sac 2-4 times daily. In severe conditions, may increase to 1 drop every hour initially.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
None Documented
None Documented
The terminal elimination half-life of fluorometholone is approximately 1.5 hours in plasma. Clinically, this short half-life allows for multiple daily dosing; however, ocular administration results in sustained local effects due to corneal binding.
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
FML (fluorometholone) is primarily metabolized in the liver, with metabolites excreted renally. Approximately 70-80% of the dose is eliminated in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 10%.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid